Cizzle Biotechnology is developing a test that could make diagnosing lung cancer more accurate by preventing false positives. Eliminating these false positives will reduce the worry for patients and save money.
A prototype has been developed. Cizzle needs to produce a monoclonal antibody, optimise reagents and validate the test. That could take two years.
The share price started at a premium on the first day of trading but ended it at 9.375p.
Cizzle is a bet on its ability to develop a commercial diagnostic test for lung cancer. The potential is enormous, and the valuation is modest....
